Reading TARA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TARA free→Reading TARA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TARA free→QuarterlyIQ Insights · TARA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 13, 2026, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…
Results of Operations and Financial Condition. On March 10, 2026, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…
Other Events. Updated Interim Results On February 27, 2026, the Company will present updated interim data from its ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) NMIBC at poster sessions at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancer Symposium in San Francisco, reporting positive results that continue to support TARA-002’s potential as a mainstay in the NMIBC treatment landscape and demonstrating meani…
Other Events. As previously disclosed, on December 8, 2025, Protara Therapeutics, Inc. (the “Company”) completed a public offering of an aggregate of 13,043,479 shares (the “Firm Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) (the “Offering”). The price to the public in the Offering was $5.75 per Firm Share. In connection with the Offering, the Company also granted the underwriters the option, for 30 days, to purchase up to an additional 1,956,521 sha…
Entry into a Material Definitive Agreement. On December 4, 2025, Protara Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to sell and issue to the Underwriters an aggregate of 13,043,479 shares (the “S…
Other Events. Updated Interim Results On December 4, 2025, the Company presented updated interim data from its ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) NMIBC at a poster session at the 2025 Annual Meeting of the Society of Urologic Oncology (SUO) Conference, reporting positive results that continue to support TARA-002’s potential as a mainstay in the NMIBC treatment landscape and demonstrating meaningful and durable activity i…
Other Events. On November 19, 2025, the Company announced interim results from its ongoing Phase 2 STARBORN-1 clinical trial of TARA-002 in pediatric patients with Lymphatic Malformations (“LMs”) during a conference call. The Company also issued the Press Release in connection with the announcement of such results. The Company reported data that highlights the potential of intracystic injection of TARA-002 in pediatric patients with LMs in its Phase 2 STARBORN-1 clinical trial, which is asses…
Results of Operations and Financial Condition. On November 10, 2025, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange A…
Results of Operations and Financial Condition. On August 11, 2025, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), o…
Results of Operations and Financial Condition. On May 8, 2025, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or o…
Other Events. On April 26, 2025, the Company presented updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with carcinoma in situ, or CIS (± Ta/T1), who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naïve, at a poster session at the 2025 AUA Conference. A copy of the poster, which has been published to the “Investors—Even…
Results of Operations and Financial Condition. On March 5, 2025, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.